A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

• Status: Recruiting
• Trial end date: 2025-07-01

Summary

This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone chemotherapy consisting of R-CHOP or polatuzumab vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma or High Grade B-Cell Lymphoma.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Peter MacCallum Cancer Centre, Australia
• Collaborator: Hoffmann-La Roche
• Treatments: Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine